Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- PCR Oncology — Arroyo Grande, California
- Sutter Auburn Faith Hospital — Auburn, California
Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- PCR Oncology — Arroyo Grande, California
- Sutter Auburn Faith Hospital — Auburn, California
- Sutter Cancer Centers Radiation Oncology Services-Auburn — Auburn, California
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achie…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05812807
Sites in California: - Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- PCR Oncology — Arroyo Grande, California
- Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
- Tower Cancer Research Foundation — Beverly Hills, California
- Marshall Cancer Center — Cameron Park, California
Phase 3 Recruiting Academic/Other
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…
Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- PCR Oncology — Arroyo Grande, California
- Sutter Auburn Faith Hospital — Auburn, California
Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in California: - Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- Enloe Medical Center — Chico, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- Epic Care-Dublin — Dublin, California
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- AIS Cancer Center at San Joaquin Community Hospital — Bakersfield, California
- Kaiser Permanente-Baldwin Park — Baldwin Park, California
- Kaiser Permanente-Bellflower — Bellflower, California
Phase 3 Recruiting NIH
This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer ret…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07391774
Sites in California: - Sutter Auburn Faith Hospital — Auburn, California
- Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
- Tower Cancer Research Foundation — Beverly Hills, California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- Memorial Medical Center — Modesto, California
Phase 3 Recruiting Industry
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early b…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06492616
Sites in California: - Comprehensive Blood & Cancer Center — Bakersfield, California
- UCSF Cancer Center Berkeley — Berkeley, California
- Cedars-Sinai Cancer Beverly Hills — Beverly Hills, California
- City of Hope National Medical Center — Duarte, California
- UCSF Wash Cancer CNTR — Fremont, California
Phase 3 Recruiting Industry
The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor recept…
Sponsor: Eli Lilly and Company
NCT ID: NCT07174336
Sites in California: - Community Cancer Institute — Clovis, California
- City of Hope — Duarte, California
- Epic Care - Emeryville — Emeryville, California
- Marin Cancer Care — Greenbrae, California
- Chao Family Comprehensive Cancer Center and Ambulatory Care (CIACC) - Irvine — Irvine, California
Phase 3 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positi…
Sponsor: Pfizer
NCT ID: NCT07062965
Sites in California: - Ventura County Hematology Oncology Specialists — Camarillo, California
- Los Angeles Cancer Network - (Admin Only / Central IDS) - No Patients — Glendale, California
- Los Angeles Cancer Network - Good Samaritan — Los Angeles, California
- Los Angeles Hematology Oncology Medical Group — Los Angeles, California
- Rolling Oaks Radiology - Oxnard — Oxnard, California
Phase 3 Recruiting Industry
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metasta…
Sponsor: BriaCell Therapeutics Corporation
NCT ID: NCT06072612
Sites in California: - Los Angeles cancer Network_Anaheim — Anaheim, California
- Comprehensive Blood and Cancer Center — Bakersfield, California
- Cedars-Sinai Cancer Beverly Hills — Beverly Hills, California
- Los Angeles Cancer Network_Corona — Corona, California
- Los Angeles cancer Network_Fountain Vallley — Fountain Valley, California
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in th…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06966700
Sites in California: - Roy and Patricia Disney Family Cancer Center ( Site 0055) — Burbank, California
- Community Cancer Institute ( Site 0100) — Clovis, California
- Providence Medical Foundation ( Site 0080) — Fullerton, California
- MemorialCare Health System - Long Beach Medical Center ( Site 9556) — Long Beach, California
- El Camino Hospital Cancer Center ( Site 0096) — Mountain View, California
Phase 3 Recruiting Industry
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in California: - Disney Family Cancer Center — Burbank, California
- City of Hope - Lennar Foundation Cancer Center — Irvine, California
- Scripps Health — La Jolla, California
- City Of Hope — Long Beach, California
- Cancer and Blood Specialty Clinic — Los Alamitos, California
Phase 3 Recruiting Industry
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Sites in California: - Clinical Trial Site — Beverly Hills, California
- Clinical Trial Site — La Jolla, California
- Clinical Trial Site — Los Alamitos, California
- Clinical Trial Site — Oakland, California
- Clinical Trial Site — Roseville, California
Phase 3 Recruiting Industry
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutati…
Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT06982521
Sites in California: - Beverly Hills Cancer Center — Beverly Hills, California
- City of Hope National Medical Center — Duarte, California
- Cedars-Sinai Medical Center — Los Angeles, California
- Stanford Women's Cancer Center — Palo Alto, California
- University of California, Davis Comprehensive Cancer Center — Sacramento, California
Phase 3 Recruiting Industry
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who ha…
Sponsor: LeonaBio
NCT ID: NCT05696626
Sites in California: - Providence Medical Foundation - Santa Rosa, CA — Santa Rosa, California
Phase 3 Recruiting Academic/Other
Latrogenic infertility as a result of cancer treatment has a profound effect on long-term quality of life in survivors of reproductive-age cancers. Oocyte cryopreservation prior to cancer treatment has been associated with improved quality…
Sponsor: University of California, San Francisco
NCT ID: NCT03011684
Sites in California: - University of California at San Francisco — San Francisco, California
Phase 2 Recruiting Academic/Other
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of …
Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04893109
Sites in California: - UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in California: - University of California Los Angeles Medical Center — Los Angeles, California
- University of California, San Diego; Moores Cancer Center — San Diego, California
- USOR Sansum Clinic — Santa Barbara, California
- Providence Medical Foundation — Santa Rosa, California
Phase 2 Recruiting Industry
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in California: - Beverly Hills Cancer Center — Beverly Hills, California
- MemorialCare Orange Coast Medical Center — Fountain Valley, California
- City of Hope at Orange County Lennar Foundation Cancer Center — Irvine, California
- LA Cancer Network — Los Angeles, California
- UCLA Department of Medicine - Hematology/Oncology — Los Angeles, California
Phase 2 Recruiting Academic/Other
The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. Partic…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT06075953
Sites in California: - Berkeley Outpatient Center — Berkeley, California
- City of Hope -Duarte Cancer Center — Duarte, California
- City of Hope - Lennar Foundation Cancer Center — Irvine, California
- UCLA — Los Angeles, California
- UCSF — San Francisco, California
Phase 1, Phase 2 Recruiting Industry
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…
Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in California: - Ellison Clinic at Saint John's — Los Angeles, California
- UCSF Medical Center at Mission Bay — San Francisco, California
Phase 2 Recruiting Industry
The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the efficacy, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive metastatic br…
Sponsor: ALX Oncology Inc.
NCT ID: NCT07007559
Sites in California: - City of Hope — Duarte, California
- UC San Diego Moores Cancer Center — La Jolla, California
- UC Irvine Health - Chao Family Comprehensive Cancer Center — Orange, California
Phase 1, Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in California: - Valkyrie Clinical Trials — Los Angeles, California
- Los Angeles Cancer Network — Los Angeles, California
- Pih Health Hematology Medical Oncology — Whittier, California
Phase 1, Phase 2 Recruiting Industry
This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents
Sponsor: AstraZeneca
NCT ID: NCT05123482
Sites in California: - Research Site — Duarte, California
- Research Site — Irvine, California
- Research Site — Santa Monica, California
- Research Site — Santa Rosa, California